Allergan Partners with TARGET PharmaSolutions to Advance NASH Research

By : on : April 20, 2017

  NEWS RELEASE Allergan Partners with TARGET PharmaSolutions to Advance NASH Research — Five-Year Study to Enroll 15,000 Adults and Children with NAFLD or NASH — —   NASH Fastest Growing Cause of Liver Cancer and Liver Transplant in the U.S. —  DUBLIN, IRELAND – April 20, 2017 — Allergan, a leading global biopharmaceutical company, announced today […]

read more

TARGET PharmaSolutions novel clinical data model helps drug industry

By : on : February 5, 2017

February 2nd, 2017 By BARRY TEATER, NCBiotech Writer Tags: Biotech & Life Science, N.C. Biotech Center When pharmaceutical companies win regulatory approval for a drug to be sold – a long and expensive journey that requires successful phase 1, 2 and 3 clinical trials – their work is far from over. They are increasingly required […]

read more

TARGET PharmaSolutions Partners with Bristol-Myers Squibb, Offering a New Platform to Collect Real World Data

CHAPEL HILL, NC – (November 10, 2016) – TARGET PharmaSolutions, Inc., a clinical data company focused on real world evidence, is pleased to announce two new collaborations with Bristol-Myers Squibb (BMY) to advance the understanding of treatment patterns in nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The TARGET model provides pharmaceutical and biotechnology partners access […]

read more

Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting

By : on : November 1, 2016

Source: Intercept Pharmaceuticals, Inc. November 01, 2016 07:05 ET Intercept Announces Ocaliva® (Obeticholic Acid) Data in PBC to be Presented at the 2016 AASLD Annual Meeting. Intercept will collaborate with academic leaders on a new NASH patient registry. NEW YORK, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept), a biopharmaceutical company focused on [...]

read more

TARGET PharmaSolutions Announces the Launch of TARGET-PBC (Primary Biliary Cholangitis)

By : on : October 5, 2016

CHAPEL HILL, NC – (October 5, 2016) – TARGET PharmaSolutions, Inc. is pleased to announce the launch of TARGET-PBC (Primary Biliary Cholangitis). TARGET-PBC is a collaborative platform created to advance the understanding of real world treatment patterns in PBC. Intercept Pharmaceuticals, Inc. (ICPT) has formed a collaboration with TARGET-PBC. “TARGET-PBC represents a unique opportunity in […]

read more

TARGET PharmaSolutions Launches Two Disease State Communities to Better Understand Real World Outcomes

CHAPEL HILL, NC – (September 30, 2016) – TARGET PharmaSolutions, Inc., a clinical data company focused on real world evidence, is pleased to announce the launch of two disease state communities: TARGET-HCC (Hepatocellular Carcinoma) and TARGET-NASH (Nonalcoholic Steatohepatitis). The TARGET model provides pharmaceutical and biotechnology partners with access to a biorepository linked to validated clinical [...]

read more

NC Biotech Center awarded $2.5M to universities and companies

By : on : May 8, 2016

RESEARCH TRIANGLE PARK, N.C. – The North Carolina Biotechnology Center awarded 36 loans and grants totaling nearly $2.5 million to universities and bioscience companies during the fourth quarter of its 2015-2016 fiscal year ending June 30. The awards support life science research, technology commercialization and entrepreneurship throughout North Carolina. They also help companies and universities […]

read more